Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials

Abstract Objective To determine the average reduction in blood pressure, prevalence of adverse effects, and reduction in risk of stroke and ischaemic heart disease events produced by the five main categories of blood pressure lowering drugs according to dose, singly and in combination. Design Meta-analysis of 354 randomised double blind placebo controlled trials of thiazides, β blockers, angiotensin converting enzyme (ACE) inhibitors, angiotensin II receptor antagonists, and calcium channel blockers in fixed dose. Subjects 40 000 treated patients and 16 000 patients given placebo. Main outcome measures Placebo adjusted reductions in systolic and diastolic blood pressure and prevalence of adverse effects, according to dose expressed as a multiple of the standard (recommended) doses of the drugs. Results All five categories of drug produced similar reductions in blood pressure. The average reduction was 9.1 mm Hg systolic and 5.5 mm Hg diastolic at standard dose and 7.1 mm Hg systolic and 4.4 mm Hg diastolic (20% lower) at half standard dose. The drugs reduced blood pressure from all pretreatment levels, more so from higher levels; for a 10 mm Hg higher blood pressure the reduction was 1.0 mm Hg systolic and 1.1 mm Hg diastolic greater. The blood pressure lowering effects of different categories of drugs were additive. Symptoms attributable to thiazides, β blockers, and calcium channel blockers were strongly dose related; symptoms caused by ACE inhibitors (mainly cough) were not dose related. Angiotensin II receptor antagonists caused no excess of symptoms. The prevalence of symptoms with two drugs in combination was less than additive. Adverse metabolic effects (such as changes in cholesterol or potassium) were negligible at half standard dose. Conclusions Combination low dose drug treatment increases efficacy and reduces adverse effects. From the average blood pressure in people who have strokes (150/90 mm Hg) three drugs at half standard dose are estimated to lower blood pressure by 20 mm Hg systolic and 11 mm Hg diastolic and thereby reduce the risk of stroke by 63% and ischaemic heart disease events by 46% at age 60-69.

[1]  D. Bennett,et al.  Blood pressure and cardiovascular disease in the Asia Pacific region. , 2003, Journal of hypertension.

[2]  J. Ménard,et al.  Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives. , 1995, Circulation.

[3]  M. Law,et al.  Risk factor thresholds: their existence under scrutiny , 2002 .

[4]  Martindale.,et al.  THE EXTRA PHARMACOPOEIA , 1937 .

[5]  Y. Seedat.  Varying responses to hypotensive agents in different racial groups: black versus white differences. , 1989, Journal of hypertension.

[6]  P. Raskin,et al.  Potassium supplementation in hypertensive patients with diuretic-induced hypokalemia. , 1985, The New England journal of medicine.

[7]  P. Lapuerta,et al.  Headache in mild-to-moderate hypertension and its reduction by irbesartan therapy. , 2000, Archives of internal medicine.

[8]  R. Glynn,et al.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. , 1987, The American journal of medicine.

[9]  C. Lewis,et al.  Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS) , 1997, Hypertension.

[10]  E. Freis,et al.  Thiazide therapy is not a cause of arrhythmia in patients with systemic hypertension. , 1988, Archives of internal medicine.

[11]  E. Raftery,et al.  TOTAL BODY AND SERUM POTASSIUM DURING PROLONGED THIAZIDE THERAPY FOR ESSENTIAL HYPERTENSION , 1975, The Lancet.

[12]  E. Freis,et al.  Early changes in plasma and urinary potassium in diuretic-treated patients with systemic hypertension. , 1984, The American journal of cardiology.

[13]  W. Hall,et al.  Cough and Angioneurotic Edema Associated with Angiotensin-Converting Enzyme Inhibitor Therapy , 1992, Annals of Internal Medicine.

[14]  E. Freis.  Critique of the clinical importance of diurectic-induced hypokalemia and elevated cholesterol level. , 1989, Archives of internal medicine.

[15]  B. Davis,et al.  Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). , 2002, JAMA.

[16]  R. Collins,et al.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies , 2002, The Lancet.

[17]  C. Lewis,et al.  Long-term effects on plasma lipids of diet and drugs to treat hypertension , 1996 .

[18]  B Neal,et al.  Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials , 2000, The Lancet.

[19]  B. Psaty,et al.  Health Outcomes Associated with Antihypertensive Therapies Used as First-Line Agents: A Systematic Review and Meta-analysis , 1998 .

[20]  P. Brennan,et al.  Effects of diuretic and beta-blocker therapy in the Medical Research Council Trial. , 1984, American Journal of Medicine.

[21]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context , 1990, The Lancet.

[22]  M. Moser.  Critique of the clinical importance of diuretic-induced hypokalemia and elevated cholesterol levels. , 1990, Archives of internal medicine.

[23]  D S Bell,et al.  Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. , 2000, New England Journal of Medicine.

[24]  ADVERSE REACTIONS TO BENDROFLUAZIDE AND PROPRANOLOL FOR THE TREATMENT OF MILD HYPERTENSION Report of Medical Research Council Working Party on Mild to Moderate Hypertension , 1981, The Lancet.

[25]  S D Walter,et al.  The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. , 1997, Journal of clinical epidemiology.

[26]  M. Woodward,et al.  Randomised trial of a perindopril-based blood pressure lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack , 2001 .

[27]  D. Coulter,et al.  Cough associated with captopril and enalapril. , 1987, British medical journal.

[28]  W. Linden.  Review: lower dose combination antihypertensive therapy is preferable to standard dose single drug therapy , 2004, ACP journal club.

[29]  C. Dollery,et al.  GLUCOSE INTOLERANCE IN HYPERTENSIVE PATIENTS TREATED WITH DIURETICS; A FOURTEEN-YEAR FOLLOW-UP , 1982, The Lancet.

[30]  J. Neoptolemos,et al.  Early prediction of severity in acute pancreatitis by urinary trypsinogen activation peptide: a multicentre study , 2000, The Lancet.

[31]  M. Law,et al.  Lowering blood pressure to prevent myocardial infarction and stroke: a new preventive strategy. , 2003, Health technology assessment.

[32]  D. Johnston.  Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack , 2001, The Lancet.

[33]  Thomas Lumley,et al.  Health outcomes associated with various antihypertensive therapies used as first-line agents , 2003 .

[34]  R. Collins,et al.  Blood pressure, stroke, and coronary heart disease Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias , 1990, The Lancet.

[35]  J. Reynolds.  Martindale : the extra pharmacopoeia , 1972 .